179 related articles for article (PubMed ID: 38489062)
1. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
2. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
[TBL] [Abstract][Full Text] [Related]
3. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
4. Biological treatments in childhood asthma.
Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis.
Kearney CM; Sangani R; Shankar D; O'Connor GT; Law AC; Walkey AJ; Bosch NA
Ann Am Thorac Soc; 2024 Jun; 21(6):866-874. PubMed ID: 38241013
[No Abstract] [Full Text] [Related]
6. Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
Nopsopon T; Barrett NA; Phipatanakul W; Laidlaw TM; Weiss ST; Akenroye A
Allergy; 2024 May; 79(5):1195-1207. PubMed ID: 38164813
[TBL] [Abstract][Full Text] [Related]
7. Safety of Biologics for Atopic Diseases During Pregnancy.
Shakuntulla F; Chiarella SE
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3149-3155. PubMed ID: 35987486
[TBL] [Abstract][Full Text] [Related]
8. Navigating biologic therapies in elderly asthma.
Ji H; Tan LD; Hafzalla GW; Nguyen N; Alismail A
Respir Med; 2024 Jun; 227():107655. PubMed ID: 38679338
[TBL] [Abstract][Full Text] [Related]
9. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
10. [The effectiveness of targeted therapy of various genetically engineered biological drugs in the treatment of bronchial asthma].
Shogenova MS; Hutueva SH; Shogenova LS
Ter Arkh; 2024 Jan; 95(12):1112-1118. PubMed ID: 38785050
[TBL] [Abstract][Full Text] [Related]
11. The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995-2015).
Almutairi KB; Inderjeeth CA; Preen DB; Keen HI; Nossent JC
Rheumatol Int; 2024 Jun; 44(6):1089-1099. PubMed ID: 38615313
[TBL] [Abstract][Full Text] [Related]
12. Thirst and drugs: A study in the World Health Organization's pharmacovigilance database.
Montastruc JL
Br J Clin Pharmacol; 2024 Jun; 90(6):1525-1528. PubMed ID: 38627211
[TBL] [Abstract][Full Text] [Related]
13. Precision care in the treatment of pediatric asthma.
Mahmood L; Keskin S; Jefferson AA
Curr Opin Pediatr; 2024 Jun; 36(3):304-309. PubMed ID: 38411592
[TBL] [Abstract][Full Text] [Related]
14. Statins and immune-mediated necrotizing myopathy: Variability in the risk.
Trenque T; Hadjoudj J; Trenque A; Tralongo F; Martin S; Azzouz B
Therapie; 2024; 79(3):365-370. PubMed ID: 37625939
[TBL] [Abstract][Full Text] [Related]
15. Use of methylphenidate and reporting of valvular heart disease: Global pharmacovigilance analysis in children and adults.
Ayme-Dietrich E; Kaguelidou F; Bertschy G; Chouchana L
Pharmacoepidemiol Drug Saf; 2024 Jun; 33(6):e5814. PubMed ID: 38837561
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of biologics used in the treatment of asthma.
Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
Hum Antibodies; 2024 Jun; ():. PubMed ID: 38905039
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety, durability of response, cessation and switching of biologics.
Mohan A; Qiu AY; Lugogo N
Curr Opin Pulm Med; 2024 May; 30(3):303-312. PubMed ID: 38426355
[TBL] [Abstract][Full Text] [Related]
18. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia).
De Las Cuevas C; Sanz EJ; de Leon J
Schizophr Res; 2024 Jun; 268():165-174. PubMed ID: 37301669
[TBL] [Abstract][Full Text] [Related]
19. Cardiac safety profile of type II kinase inhibitors: Analysis of post-marketing reports from databases of European Medicine Agency & World Health Organization.
Khurana A; Arora MK; Dubey H
Daru; 2023 Dec; 31(2):107-118. PubMed ID: 37221442
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of dupilumab versus benralizumab and mepolizumab.
Bleecker E; Blaiss M; Jacob-Nara J; Huynh L; Guo T; Ye M; Stanford RH; Wang Z; Soler X; Nag A; Nair R; Borsos K
Allergy Asthma Proc; 2024 May; ():. PubMed ID: 38760161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
